Skip to content

Pathos AI

Oncology drugs matched to the right patients

Raised to date

$237.5M

of $300M offered across 1 Form D filing

Still open
$62.5M
Investors
13
Last filed
Nov 18, 2026

About

Pathos AI is a clinical-stage biotech building oncology therapies using a large collection of multimodal patient data and proprietary AI models. Its AI agents analyze that data and simulate trial scenarios to identify the patient populations most likely to respond, and it runs adaptive trials with small teams. It was founded in 2022 by Eric Lefkofsky and Ryan Fukushima and partners with biopharma companies.

Uses millions of oncology patient records combined with proprietary AI models to select the patients most likely to respond before and during clinical trials.

Funding

  • EquityFiled Nov 18, 2026Form D
    $237.5M/ $300M

Product

Pathos AI drug development platform

AI-enabled drug development

A data and AI platform that combines oncology patient records, biological modeling and thousands of AI agents to select trial populations and support Go/No-Go decisions.

  • Large collection of multimodal oncology patient data
  • Proprietary data model with AI agents that simulate trial scenarios
  • Adaptive trial design run by small AI-enabled teams

Built for

Oncology patients, biopharma partners and investors in drug development

People on file